Primary cutaneous aspergillosis--an emerging infection among immunocompromised patients.
T J
TJ
Walsh
D017088:AIDS-Related Opportunistic Infections / Q000276:immunology / Q000382:microbiology; D000666:Amphotericin B / Q000627:therapeutic use; D000935:Antifungal Agents / Q000627:therapeutic use; D001228:Aspergillosis / Q000188:drug therapy / Q000276:immunology* / Q000382:microbiology; D001230:Aspergillus / Q000276:immunology* / Q000302:isolation & purification; D003881:Dermatomycoses / Q000188:drug therapy / Q000276:immunology* / Q000382:microbiology; D006801:Humans; D016867:Immunocompromised Host; D011379:Prognosis
D000935:Antifungal Agents; D000666:Amphotericin B